Антибиотикоассоциированная диарея у детей

1. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15: 573–81.
2. Beaugerie L, Flahault A, Barbut F et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003; 17: 905–12.
3. Bouhnik Y. Microflora and diarrhoea: antibiotic-associated diarrhoea. Rambaut JC, Buts JP (ets.). Gut Microflora. Paris: John Libbey Eurotex, 2006; 181–97.
4. Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2,462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43–50.
5. McFarland LV, Brandmarker SA, Guandalini S. Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gasroenterol Nutr 2000; 31: 220–31.
6. Delmee M, Verellen G, Avesani V et al. Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr 1988; 147: 36–40.
7. Larson HE, Barclay FE, Honour P et al. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146: 727–33.
8. Ferroni A, Merckx J, Ancelle T et al. Nosocomial outbreak of Clostridium difficile diarrhea in a pediatric service. Eur J Clin Microbiol Infect Dis 1997; 16: 928–33.
9. Buts JP. The clinical significance of Clostridium difficile infections in
infants and children. Rambaud JC, LaMont JT eds.). Updates of Clostridium
difficile. Paris: Springer-Verlag, 1996; 29–36.
10. Benoit R, Danquechin DE, Loulergue J et al. Diarroea post-antibiotique:
role de Klebsiella oxytoca. Gasroenterol Clin Biol 1992; 16: 860–4.
11. Lamont JT. Recent advances in the structures and function of
Clostridium difficile toxins. Rambaud JC, LaMont JT (eds.). Updates of
Clostridium difficile. Paris: Springer-Verlag, 1996; 72–86.
12. Price AB. Pseudomembranous colitis. Wright R (ed.). Recent
advances in gastroenterology. London, WB Saunders, 2005; 15–172.
13. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associatied
diarrhea: a review. Arch Intern Med 2000; 161: 5–33.
14. Cooperstock M. Clostridium difficile in infants and children. Rambaud JC, Ducluzeau R (eds.). Clostridium difficile-associated intestinal
diseases. Paris: Springer-Verlag, 1990; 81–94.
15. Harris PR, Figueroa-Colon R. Rectal prolapse in children associated
with Clostridium difficile infection. Pediatr Infect Dis J 1995; 14: 78-80.
16. Garlani MJ, Murray JC, Morad AB et al. Chronic osteomyelitis caused
by Clostridium difficile in an adolescent with sickle cell disease. Pediatr
Infect Dis J 1996; 15: 1054–6.
17. Thomas DFM, Fernie DS, Bayston R et al. Clostridial toxins in neonatal
necrotising enterocolitis. Arch Dis Child 1984; 59: 270–83.
18. Cetina-Sauri G, Sierra Basto G. Therapeutic evaluation of Saccharomyces
boulardii in children with acute diarrhea. Annales de Pediatrie
1994; 41 (6): 397–400.
19. Castaneda C, Garcia E, Santa Cruz M et al. Effects of Saccharomyces
boulardii in children with chronic diarrhea, especially cases
due to giardiasis. Revista Mexicana de Puericultura y Pediatria 1995; 2: 12.
20. Castagliuolo I, LaMont JT, Nikulasson ST et al. Saccharomyces
boulardii protease inhibits Clostridium difficile toxin A effects in the
rat ileum. Infect Immun 1996; 12: 5225–32.
21. Gedek BR. Adherence of E. coli serogroup O-157 and the Salmonella
typhimurium mutant DT 104 to the surface of Saccharomyces
boulardii. Mycoses 1999; 42 (4): 261–4.
22. Cherucka D, Dahan S, Mograbi B et al. Saccharomyces boulardii
preserves the barrier function and modulates the signal transduction
pathway induced in enteropathogenic Escherichia coli-infected T84
cells. Infect Immun 2000; 68: 5998–6004.
23. Dahan S, Dalmasso G, Imbert V et al. Saccharomyces boulardii
interferes with enterohemorrhagic Escherichia coli-induced signaling
pathways in T84 cells. Infect Immun 2003; 72 (2): 766–73.
24. Buts JP, Bernasconi P, Van Craymest MP et al. Response of human
and rat small intestinal mucosa to oral administration of Saccharomyces
boulardii. Pediatric Res 1986; 20: 192–6.
25. Sougiolzis S. Saccharomyces boulardii produces a soluble antiinflammatory
factor that inhibits NF-kB-mediated IL-8 gene expression.
Biochem Biophys Res Commun 2006; 2: 23.
26. Girard-Pipau F, Pompei A, Schneider S et al. Intestinal microflora,
short chain and cellular fatty acids, influence of a probiotic Saccharomyces
boulardii. Microb Ecolog Health Dis 2002; 14: 220–7.
27. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for
Clostridium difficile- associated entheropathies in infants. J Pediatr
Gastroenterol Nutr 1993; 16: 419–25.
28. Costalos C, Skouteri V, Gounaris A et al. Enteral feeding of premature
infants with Saccharomyces boulardii. Early Hum Dev 2003; 11:
89–96.